KR20170132293A - 글루타메이트 옥살로아세테이트 트랜스아미나제 1（ｇｏｔ１） 제제와 이의 제조방법 및 용도 - Google Patents

글루타메이트 옥살로아세테이트 트랜스아미나제 1（ｇｏｔ１） 제제와 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR20170132293A
KR20170132293A KR1020177031382A KR20177031382A KR20170132293A KR 20170132293 A KR20170132293 A KR 20170132293A KR 1020177031382 A KR1020177031382 A KR 1020177031382A KR 20177031382 A KR20177031382 A KR 20177031382A KR 20170132293 A KR20170132293 A KR 20170132293A
Authority
KR
South Korea
Prior art keywords
got1
polypeptide
sumo
protein
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177031382A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 미렐만
아론 라빈코프
안젤라 루반
길 요나
엘리 하줌
블라다스 부멜리스
네리저스 마카우스카스
사울레 수드지우비엔느
엘레나 나르몬테이트
Original Assignee
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 filed Critical 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드
Publication of KR20170132293A publication Critical patent/KR20170132293A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01001—Aspartate transaminase (2.6.1.1), i.e. aspartate-aminotransferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
KR1020177031382A 2015-03-31 2016-03-31 글루타메이트 옥살로아세테이트 트랜스아미나제 1（ｇｏｔ１） 제제와 이의 제조방법 및 용도 Withdrawn KR20170132293A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140492P 2015-03-31 2015-03-31
US62/140,492 2015-03-31
PCT/IL2016/050346 WO2016157190A1 (en) 2015-03-31 2016-03-31 Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof

Publications (1)

Publication Number Publication Date
KR20170132293A true KR20170132293A (ko) 2017-12-01

Family

ID=55795016

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177031382A Withdrawn KR20170132293A (ko) 2015-03-31 2016-03-31 글루타메이트 옥살로아세테이트 트랜스아미나제 1（ｇｏｔ１） 제제와 이의 제조방법 및 용도

Country Status (11)

Country Link
US (1) US20180071369A1 (enExample)
EP (1) EP3277308A1 (enExample)
JP (1) JP2018511325A (enExample)
KR (1) KR20170132293A (enExample)
CN (1) CN107771217A (enExample)
AU (1) AU2016242298A1 (enExample)
BR (1) BR112017021016A2 (enExample)
CA (1) CA2979309A1 (enExample)
HK (1) HK1243329A1 (enExample)
RU (1) RU2017135552A (enExample)
WO (1) WO2016157190A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018229764A1 (en) 2017-06-13 2018-12-20 Yeda Research And Development Co. Ltd. Treatment of advanced or progressive multiple sclerosis
RU2712193C1 (ru) * 2018-07-27 2020-01-24 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Способ лечения поражения нервной системы с помощью рекомбинантной глутаматоксалоацетаттрансаминазы
US11740211B2 (en) * 2020-01-31 2023-08-29 Waters Technologies Corporation LC/MS adduct mitigation by vapor deposition coated surfaces
CN116143898B (zh) * 2023-01-30 2026-03-24 翌圣生物科技(上海)股份有限公司 骨形态发生蛋白bmp-2重组蛋白、编码基因及其原核表达方法
CN118147225A (zh) * 2024-03-25 2024-06-07 华中农业大学 黄颡鱼去sumo化修饰体系及其构建方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2472477C (en) * 2002-01-07 2012-03-20 Lifesensors, Inc. Methods and compositions for protein expression and purification
EP2561889A3 (en) * 2002-08-01 2013-04-03 Yeda Research and Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
EP1765857A2 (en) * 2004-07-02 2007-03-28 Metanomics GmbH Process for the production of fine chemicals
CA2585798A1 (en) * 2004-12-17 2006-06-17 Metanomics Gmbh Process for the control of production of fine chemicals
US8119369B2 (en) 2004-12-30 2012-02-21 Lifesensors, Inc. Human SUMO-3 for enhancing protein expression
US20100048480A1 (en) * 2006-11-22 2010-02-25 Bettina Bommarius Production of anti-microbial peptides
JP5469786B2 (ja) * 2006-12-29 2014-04-16 ライフセンサーズ、インク． タンパク質の発現増強および精製の方法および組成
PT2415779E (pt) * 2010-08-02 2015-05-13 Ratiopharm Gmbh Processo de produção e purificação de uma sialiltransferase solúvel activa
EP2714727B1 (en) * 2011-05-24 2014-10-22 Asociación Centro de Investigación Cooperativa en Biociencias-CIC Biogune High affinity sumo traps

Also Published As

Publication number Publication date
JP2018511325A (ja) 2018-04-26
HK1243329A1 (zh) 2018-07-13
CN107771217A (zh) 2018-03-06
WO2016157190A1 (en) 2016-10-06
US20180071369A1 (en) 2018-03-15
EP3277308A1 (en) 2018-02-07
AU2016242298A1 (en) 2017-10-19
RU2017135552A (ru) 2019-04-30
RU2017135552A3 (enExample) 2019-07-24
CA2979309A1 (en) 2016-10-06
BR112017021016A2 (pt) 2018-07-03

Similar Documents

Publication Publication Date Title
US12286468B2 (en) Scaffold proteins
AU650893B2 (en) O-glycosylated alpha-2 interferon
RU2159814C2 (ru) Аналог эритропоэтина
TWI454482B (zh) 在活體中具有延長之半生期以及提高之紅血球生成活性的重組人類紅血球生成素（ｅｐｏ)-ｆｃ融合蛋白
ES2383300T3 (es) Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
KR100545720B1 (ko) 당화된 면역글로불린 및 이를 포함하는 면역접합체
US20200246420A1 (en) pHLIP® peptide-mediated epitope tethering at cell surfaces
JP2009538283A (ja) エリスロポエチン組成物
Lu et al. Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: effect on stability and biological activity
EP0486525A1 (en) STABILIZED PROTEIN OR PEPTIDE CONJUGATES.
KR20130122764A (ko) 항암 융합 단백질
US20180071369A1 (en) Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof
CA2607844C (en) Pegylated g-csf polypeptides and methods of producing same
CZ98297A3 (cs) Způsob purifikace keratinocytových růstových faktorů
Wang et al. Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli
EP0550769B1 (en) Use of hepatocyte growth factors for the manufacture of a hemopoietic stem cell augmenting agent
CN105085658B (zh) 一种白细胞介素29突变体及聚乙二醇衍生物
JP2012511309A (ja) Ｅｃ−ｓｏｄのカルボキシル末端のアポプチンタンパク質導入ドメインの融合蛋白質
KR20040083268A (ko) 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
KR101330033B1 (ko) 인간 과립구 콜로니 자극 인자(ｇ-ｃｓｆ)의 변이체를 포함하는 허혈성 질환 치료용 약학 조성물
KR20080042747A (ko) 신규한 융합 단백질, 이를 발현하는 세포주 및 이의 제조방법
CN108463730A (zh) 包含重组人促甲状腺激素的组合物以及生产重组人促甲状腺激素的方法
RU2805879C1 (ru) Штамм линии клеток яичника китайского хомячка
JP2021510683A (ja) インビボ持続放出性組換え凝固因子ｖｉｉｉ及びその調製方法
KR100502855B1 (ko) 인간 트롬보포이에틴 변이체 및 그의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171030

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination